Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nutr Cancer ; 63(5): 763-70, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21660856

RESUMO

Tocotrienols (Toc3) have been suggested to possess anticancer effects besides antioxidant and antiinflammatory effects. Previous studies have demonstrated that Toc3 induce apoptosis in epithelial carcinoma. However, the effects of Toc3 on malignant hematopoietic cells have not yet been thoroughly investigated. We investigated Toc3-induced apoptosis in human hematological cancer cell lines. α-, δ-, and γ-Toc3 induced concentration-dependent apoptosis, and γ-Toc3 demonstrated more effective induction than the other Toc3 derivatives in HL-60 cells. γ-Toc3 may have induced apoptosis by activation of the caspase cascade, cytochrome c (Cyt.c) release, Bid cleavage, and mitochondorial membrane depolarization in HL-60, NB-4, Raji, and SY-5Y cells. Furthermore, 10-30 µM γ-Toc3 showed cytotoxicity for leukemic cells from various patients regardless of lymphoblastic, myeloblastic, or relapsed leukemia, but the cytotoxic effect was weak in normal mononuclear cells, interestingly. γ-Toc3 may have a role in cancer prevention and potential for treating hematological malignancies.


Assuntos
Antineoplásicos Fitogênicos/metabolismo , Proteínas Reguladoras de Apoptose/metabolismo , Apoptose , Cromanos/metabolismo , Neoplasias Hematológicas/metabolismo , Leucemia/metabolismo , Mitocôndrias/metabolismo , Vitamina E/análogos & derivados , Adolescente , Proteína Agonista de Morte Celular de Domínio Interatuante com BH3/metabolismo , Células da Medula Óssea/metabolismo , Células da Medula Óssea/patologia , Caspases/metabolismo , Linhagem Celular Tumoral , Núcleo Celular/patologia , Proliferação de Células , Células Cultivadas , Criança , Pré-Escolar , Citocromos c/metabolismo , Fragmentação do DNA , Feminino , Neoplasias Hematológicas/patologia , Neoplasias Hematológicas/prevenção & controle , Humanos , Lactente , Leucemia/patologia , Leucemia/prevenção & controle , Masculino , Potencial da Membrana Mitocondrial , Mitocôndrias/patologia , Proteínas de Neoplasias/metabolismo , Vitamina E/metabolismo
2.
J Int Acad Periodontol ; 10(3): 95-102, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18714935

RESUMO

Periodontitis, which is a widespread and major dental disease, is a multifactorial, lifestyle-related disease and has been analyzed for gene polymorphism. We examined the frequency of the polymorphisms of the pro-inflammatory cytokine genes IL-1 A (-889) and IL-1 B (+3953) in relation to periodontitis in the Japanese population. We also examined whether polymorphism of TLR2 (Arg677Trp) and TLR4 (Asp299Gly), which are receptors recognized by periodontopathic bacteria, may also be associated with periodontitis. The subjects were 92 Japanese individuals, among whom 43 had periodontitis and 49 were healthy controls. We isolated genomic DNA from lingual mucosal cells and tested them for single nucleotide polymorphisms by polymerase chain reaction-restriction fragment length polymorphism. The incidence of polymorphisms was analyzed statistically by Fisher's exact test, and the sensitivity and specificity of the gene polymorphisms were calculated. The purpose was to determine whether such polymorphisms might be effectively used in the diagnosis of periodontitis. However, we found no evidence that the gene polymorphism of IL-1A (p = 0.082), IL-1 B (p = 0.180), TLR2 (p = 1.000) or TLR4 (p = 1.000) and overall gene polymorphism in any of the genes (p = 0.752) correlate with periodontitis. The sensitivity (14.0%) and specificity (83.7%) of the mutations found in all of the genes were low. Therefore, we advise against using the analyses of polymorphism of these genes to detect periodontitis in the Japanese population.


Assuntos
Interleucina-1alfa/genética , Interleucina-1beta/genética , Periodontite/imunologia , Polimorfismo Genético/genética , Receptor 2 Toll-Like/genética , Receptor 4 Toll-Like/genética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Arginina/genética , Ácido Aspártico/genética , Glicina/genética , Humanos , Japão , Pessoa de Meia-Idade , Mutação/genética , Periodontite/genética , Periodontite/microbiologia , Reação em Cadeia da Polimerase , Polimorfismo de Fragmento de Restrição , Polimorfismo de Nucleotídeo Único/genética , Sensibilidade e Especificidade , Triptofano/genética
4.
Blood ; 107(12): 4663-5, 2006 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-16478880

RESUMO

Although infants with acute lymphoblastic leukemia (ALL) and a germline MLL gene have a better prognosis than comparable infants with a rearranged MLL gene, their optimal therapy is controversial. In 2 consecutive studies, conducted between 1996 and 2002, we treated 22 cases of infant ALL with germline MLL using chemotherapy alone. The 5-year event-free survival rate was 95.5% with a 95% confidence interval of 86.9 to 100%. All 21 infants with precursor B-cell ALL have been in first complete remission for 3.5 to 8.8 years. Most treatment-related toxicities were predictable and well tolerated, and neither secondary malignancies nor physical growth impairments have been observed. These results indicate that chemotherapy of the type described here is both safe and highly effective against infant precursor B-cell ALL with MLL in the germline configuration.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Linfoma de Burkitt/tratamento farmacológico , Proteína de Leucina Linfoide-Mieloide , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Linfoma de Burkitt/genética , Linfoma de Burkitt/mortalidade , Intervalo Livre de Doença , Feminino , Histona-Lisina N-Metiltransferase , Humanos , Lactente , Japão , Masculino , Proteína de Leucina Linfoide-Mieloide/genética , Indução de Remissão , Estudos Retrospectivos , Taxa de Sobrevida
6.
J Nutr Sci Vitaminol (Tokyo) ; 50(3): 219-21, 2004 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15386935

RESUMO

All-trans retinoic acid (ATRA) is used as differentiation therapy for acute promyelocytic leukemia (APL). The two major adverse effects of ATRA therapy are hyperleukocytosis and retinoic acid syndrome. In order to prevent these adverse effects, low-dose ATRA therapy (25 mg/m2/d) has been tried in adults. Accordingly we assessed the pharmacokinetics of low-dose ATRA in children with cancer. Four children (one with APL and three with other advanced cancer) were administered ATRA and its pharmacokinetics were evaluated. In three patients, the pharmacokinetic parameters of ATRA were similar to those previously determined for APL patients in remission, but the values were lower in one patient. Low-dose ATRA was effective for APL, but not for the solid tumors. This therapy did not cause any severe toxicity. Further studies are needed to determine the optimum ATRA regimen and to evaluate low-dose ATRA combined with chemotherapy in children with APL.


Assuntos
Leucemia Promielocítica Aguda/tratamento farmacológico , Neoplasias/tratamento farmacológico , Tretinoína/administração & dosagem , Tretinoína/farmacocinética , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Japão , Leucocitose/induzido quimicamente , Masculino , Indução de Remissão , Tretinoína/efeitos adversos
8.
Cancer Chemother Pharmacol ; 53(3): 204-8, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-14634792

RESUMO

PURPOSE: To determine the minimum levels of L-asparaginase (ASNase) activity necessary to maintain L-asparagine (Asn) depletion under ASNase treatment in acute lymphoblastic leukemia (ALL). METHODS: We measured ASNase activity using an enzyme coupling method with a limit of detection of 2 U/l and examined the relationship between ASNase activity and Asn levels in blood samples from 14 children with ALL. RESULTS: In all but one patient showing high ASNase antibody titers, minimum ASNase activity to maintain Asn depletion levels below the limit of detection (40 ng/ml) ranged from 6 to 180 U/l with a median value of 16 U/l. In 11 patients, the enzyme activity corresponding to minimum detectable Asn levels ranged from 2 to 32 U/l with a median value of 6.5 U/l. Patients with an ASNase activity of 2 U/l or an undetectable activity (<2 U/l) had nearly normal Asn levels: 4140+/-1161 ng/ml at 2 U/l and 7235+/-3107 ng/ml at <2 U/l (mean+/-SD). Statistical analysis showed that ASNase activity in the range of 2-32 U/l was inversely correlated with Asn levels ( r=-0.803, P=0.001). CONCLUSION: These results show that Asn levels are strongly correlated with plasma ASNase activity even at low enzyme activities (<50 U/l) and that this sensitive ASNase assay can be used to estimate plasma Asn depletion levels.


Assuntos
Antineoplásicos/uso terapêutico , Asparaginase/uso terapêutico , Asparagina/sangue , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Antineoplásicos/sangue , Asparaginase/sangue , Asparaginase/metabolismo , Criança , Humanos , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangue
9.
Free Radic Res ; 37(9): 1037-42, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-14670011

RESUMO

Alpha-tocopherol (a form of vitamin E) is a fat-soluble vitamin that can prevent lipid peroxidation of cell membranes. This antioxidant activity of alpha-tocopherol can help to prevent cardiovascular disease, atherosclerosis and cancer. We investigated the alpha-tocopherol level and the expression of alpha-tocopherol transfer protein (alpha-TTP) in the leukocytes of children with leukemia. The plasma and erythrocyte alpha-tocopherol levels did not differ between children with leukemia and the control group. However, lymphocytes from children with leukemia had significantly lower alpha-tocopherol levels than lymphocytes from the controls (58.4 +/- 39.0 ng/mg protein versus 188.9 +/- 133.6, respectively; p < 0.05), despite the higher plasma alpha-tocopherol/cholesterol ratio in the leukemia group (5.83 +/- 1.64 micromol/mmol versus 4.34 +/- 0.96, respectively; p < 0.05). No significant differences in the plasma and leukocyte levels of isoprostanes (the oxidative metabolites of arachidonic acid) were seen between the leukemia patients and controls. The plasma level of acrolein, a marker of oxidative stress, was also similar in the two groups. Investigation of alpha-TTP expression by leukocytes using real-time PCR showed no difference between the two groups. These findings suggest that there may be comparable levels of lipid peroxidation in children with untreated leukemia and controls, despite the reduced alpha-tocopherol level in leukemic leukocytes.


Assuntos
Proteínas de Transporte/biossíntese , Leucemia/metabolismo , Leucócitos/metabolismo , alfa-Tocoferol/metabolismo , Acroleína/análise , Acroleína/metabolismo , Antioxidantes/análise , Antioxidantes/metabolismo , Criança , Pré-Escolar , Feminino , Humanos , Isoprostanos/análise , Isoprostanos/metabolismo , Peroxidação de Lipídeos/fisiologia , Masculino , Estresse Oxidativo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , alfa-Tocoferol/análise
11.
Free Radic Res ; 37(9): 1037-1042, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-28447530

RESUMO

α-Tocopherol (a form of vitamin E) is a fat-soluble vitamin that can prevent lipid peroxidation of cell membranes. This antioxidant activity of α-tocopherol can help to prevent cardiovascular disease, atherosclerosis and cancer. We investigated the α-tocopherol level and the expression of α-tocopherol transfer protein (α-TTP) in the leukocytes of children with leukemia. The plasma and erythrocyte α-tocopherol levels did not differ between children with leukemia and the control group. However, lymphocytes from children with leukemia had significantly lower α-tocopherol levels than lymphocytes from the controls (58.4±39.0 ng/mg protein versus 188.9±133.6, respectively; p<0.05), despite the higher plasma α-tocopherol/cholesterol ratio in the leukemia group (5.83±1.64 µmol/mmol versus 4.34±0.96, respectively; p<0.05). No significant differences in the plasma and leukocyte levels of isoprostanes (the oxidative metabolites of arachidonic acid) were seen between the leukemia patients and controls. The plasma level of acrolein, a marker of oxidative stress, was also similar in the two groups. Investigation of α-TTP expression by leukocytes using real-time PCR showed no difference between the two groups. These findings suggest that there may be comparable levels of lipid peroxidation in children with untreated leukemia and controls, despite the reduced α-tocopherol level in leukemic leukocytes.

12.
Cancer Res ; 62(8): 2203-9, 2002 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-11956069

RESUMO

The candidate tumor suppressor p33(ING1) plays an important role in inducinggrowth arrest at G(0)-G(1) phase of the cell cycle and/or promoting apoptosis in cancerous cells. p33(ING1) is reported to act as a transcriptional cofactor by associating with tumor suppressor p53, HAT, or histone deacetyltransferase, suggesting that p33(ING1) is involved in chromatin-mediated transcriptional regulation. However, the molecular mechanism of p33(ING1)-mediated transcriptional regulation is poorly understood. Here we analyzed expression profiles in mouse mammary epithelial cells (NMuMG) by using a cDNA microarray consisting of 2304 mouse cDNAs after inducing transformation with antisense inhibitor of growth 1 (ING1) in retrovirus vector. The subsequent confirmation of the altered expression levels of the selected genes by semiquantitative reverse transcription-PCR demonstrated that overexpression of the antisense ING1 stimulated expression of 14 genes, which included cyclin B1, 12-O-tetradecanoylphorbol-13-acetate-inducible sequence 11, proto-oncogene DEK, and osteopontin, whereas we have detected transcriptional repression of 5 genes, including TPT1. In addition, adenovirus-mediated overexpression of ING1 in NMuMG cells resulted in down-regulation of cyclin B1, 12-O-tetradecanoylphorbol-13-acetate-inducible sequence 11, DEK, and osteopontin, whereas the levels of TPT1 expression were increased. The further analysis using p53(-/-) SAOS2 cells showed that the p33(ING1)-induced cyclin B1 down-regulation was p53 dependent. Thus, our cDNA microarray analysis suggested that p33(ING1) targets the multiple genes, including proto-oncogene DEK and cyclin B1, at least some of which are regulated in a p53-dependent manner, in the cells undergoing cell growth or apoptosis.


Assuntos
Ciclina B/genética , Proteínas de Drosophila , Glândulas Mamárias Animais/fisiologia , Proteínas/fisiologia , Receptores Proteína Tirosina Quinases/genética , Receptores da Família Eph , Animais , Proteínas de Ciclo Celular , Linhagem Celular , Ciclina B/biossíntese , Ciclina B1 , DNA Antissenso/genética , DNA Antissenso/farmacologia , Proteínas de Ligação a DNA , Células Epiteliais/metabolismo , Células Epiteliais/fisiologia , Perfilação da Expressão Gênica , Regulação da Expressão Gênica , Genes Supressores de Tumor , Inibidores do Crescimento/genética , Inibidores do Crescimento/fisiologia , Humanos , Proteína 1 Inibidora do Crescimento , Peptídeos e Proteínas de Sinalização Intracelular , Glândulas Mamárias Animais/citologia , Glândulas Mamárias Animais/metabolismo , Camundongos , Proteínas Nucleares , Análise de Sequência com Séries de Oligonucleotídeos , Proteínas/genética , Proto-Oncogene Mas , Receptores Proteína Tirosina Quinases/biossíntese , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Células Tumorais Cultivadas , Proteína Tumoral 1 Controlada por Tradução , Proteína Supressora de Tumor p53/biossíntese , Proteína Supressora de Tumor p53/genética , Proteína Supressora de Tumor p53/fisiologia , Proteínas Supressoras de Tumor
13.
Mol Pharmacol ; 61(3): 533-45, 2002 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11854433

RESUMO

A large number of structurally diverse compounds act as open-channel blockers of NMDA receptors. They may share discrete or overlapping binding sites within the channel. In this study, the effects of mutations in and around the membrane-spanning and pore-forming regions of NMDA receptor subunits were studied with three blockers, MK-801, memantine, and TB-3-4, using recombinant NMDA receptors expressed in Xenopus laevis oocytes. Mutations at the critical asparagine residues in the M2 loop of NR1 and NR2B and at a tryptophan residue in M2 of NR2B reduced block by MK-801, memantine, and TB-3-4. Mutations at residues in the pre-M1, M1, M3, post-M3, and post-M4 regions had differential effects on the three blockers. Many mutations in these regions reduced block by MK-801 and TB-3-4 but had no effect on block by memantine. The differential effects on block by memantine and MK-801 are unlikely to be caused by differences in the size of these blockers. Benzyl rings in MK-801 and TB-3-4 may make hydrophobic interactions with aromatic and hydrophobic amino acid residues in the pore. Some mutations in the pre-M1 and M3 regions generated constitutively open channels, characterized by large holding currents. The effects of the various mutants are discussed in the context of models based on the known structure of the pore of the KcsA potassium channel and on previous studies dealing with solvent accessible residues in NMDA receptor subunits as determined by modification after cysteine mutagenesis.


Assuntos
Antagonistas de Aminoácidos Excitatórios/farmacologia , Receptores de N-Metil-D-Aspartato/metabolismo , Vestíbulo do Labirinto/efeitos dos fármacos , Sequência de Aminoácidos , Animais , Maleato de Dizocilpina/farmacologia , Memantina/farmacologia , Proteínas de Membrana/química , Proteínas de Membrana/efeitos dos fármacos , Proteínas de Membrana/genética , Proteínas de Membrana/metabolismo , Camundongos , Modelos Moleculares , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Oócitos/efeitos dos fármacos , Oócitos/metabolismo , Conformação Proteica , Estrutura Terciária de Proteína , Ratos , Receptores de N-Metil-D-Aspartato/química , Receptores de N-Metil-D-Aspartato/efeitos dos fármacos , Receptores de N-Metil-D-Aspartato/genética , Homologia de Sequência de Aminoácidos , Vestíbulo do Labirinto/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...